DAFTAR ISI

PENELITIAN

Creatine Kinase Myocardial Band, Myeloperoxidase, Matrix Metalloproteinase-9 dan Troponin T Pada IMA
(The Creatine Kinase Myocardial Band, Myeloperoxidase, Matrix Metalloproteinase-9 Activities and Troponin T in Myocardial Infarction)
IA Hutagalung, I Patellongi, R Pakasi, M Arif, AA Mappahya, Hardjoeno ............................................................. 127–133

D-Dimer Penderita Sindrom Koroner Akut dan Stenosis
(D-Dimer in Acute Coronary Syndrome and Stenosis)
Birhasani, Lisyani BS, Ria T ................................................................. 134–138

Imunokimiaiwi PGE2 Usus Ileum yang Kekurangan Energi Protein
(Immunohistochemistry of PGE2 Ileum Intestine Protein Energy Deficiency)
R. Heru Prasetyo ............................................................................. 143–145

Gamma-glutamyltransferase dan Apolipoprotein B dengan Sindroma Metaboli
(Gamma-glutamyltransferase and Apolipoprotein B with the Metabolic Syndrome)
Tahono, M.I. Diah Pramudianti .............................................................. 146–150

Umbi Ubi Jalar Ungu Bali (Ipomoea batatas) di Transaminase Serum, Malondialdehyde Hepar dan Alkohol Kronis
(Balinese Purple Sweet Potato (Ipomoea batatas L) on SGOT, SGPT, MDA level and Chronic Alcohol)

Leukosit Infeksi Bakteri Sistemik
(Leucocyte in Systemic Bacterial Infections)
Meita Hendrianingtyas, MI. Tjahjati DM ................................................. 155–158

Meningitis Tuberculosis
(Meningitis Tuberculosis)
Silvia Rachmayati, Ida Parwati, A Rizal, D Oktavia .................................. 159–162

Platelet Aggregation In Acute Coronary Syndrome
(Aggregasi Trombosit di Sindroma Koroner Akut)
Sulianty, Adi K Aman ........................................................................ 163–165

TELAH PUSTA

Pemetaan Epitop dan Aplikasi Klinisnya
(Epitope Mapping and It’s Clinical Aplication)
Jusak Nugraha .................................................................................. 166–170

INFORMASI LABORATORIUM MEDIK TERBARU ........................................... 176–177
PLATELET AGGREGATION IN ACUTE CORONARY SYNDROME
(Aggregasi Trombosit di Sindroma Koroner Akut)

Sulianty, Adi K Aman

ABSTRACT

Haemostatic system is the mechanism that controls response of bleeding or thrombosis, so that thrombogenesis and fibrinolysis are in balance. Obstruction of brain and heart vascular system often occurred, because of the hyperactivity of thromboses function that causes thrombosis. CBC, blood glucose, lipid profile and cardiac enzyme assay were performed on acute coronary syndrome patients at the Emergency Department as well as at the normal control. In this study, each group consist of 10 patients. Platelet aggregation test was measured with turbidimetric method using Helena Agram aggregometer. ADP and epinephrine 5 and 10 µM were used as the agonists. There was significant difference in the mean total cholesterol, LDL and blood sugar level in the acute coronary syndrome patients than the control group. Platelet aggregations with ADP 1 and 5 µM were significantly different in the acute coronary syndrome patients than the control one. In this study were found patients aged above 50 years old have platelet aggregation with ADP 10 µM, which differ significantly than the control group.

Key words: Platelet aggregation, acute coronary syndrome

INTRODUCTION

Hemostatic system is the mechanism that control bleeding and coagulation, so that coagulation and fibrinolysis are in balance. The role of thrombosis in haemostatic is to make the thrombosis plug, that start from platelet adhesion, shape change, granule secretion, aggregation and finally the activation of coagulation cascade by the thrombosis membrane.1–5

The acute coronary syndrome (ACS) consists of unstable angina pectoris (UAP), ST Elevation in Myocardial Infarct (STEMI) and Non ST Elevation Myocardial Infarct (NSTEMI). This acute coronary syndrome basic of atherosclerosis cause the formation of atheroma plaque.6,7 The obstruction of brain and heart vascularization often occur because of the thrombosis function hyperactivity, that cause thrombosis. Platelet aggregation test is performed to know the platelet function, most often carried out by the analyzer using a turbidimeter method (change by light transmission).8–10

The objective of this study is to know platelet aggregation function in an acute coronary syndrome.

METHODS

The Study Population

This study is carried out by a cross sectional method. There were included ten acute coronary syndrome patients (1 woman and 9 men) at the Emergency Department and ten normal persons were chosen for control, and were examined from October until December 2010. The diagnosis of acute coronary syndrome is established by a cardiologist from the patient’s clinical symptoms, ECG specific for acute coronary syndrome and cardiac enzymes. Exclusion criteria are: patients who consume anti thrombosis...
drugs, NSAID and hormonal contraception, history of hereditary bleeding disturbance, chronic renal failure and dyslipidemia.

The Biochemical Analysis

The patient’s blood were drawn into EDTA (Etilen Diamine Tetra-acetic Acid) tube for CBC (Complete Blood Count), 4 (four) silicone treated glass tubes with 3.6 mL of its volume with natrium citrate 3.6% to obtain platelet rich plasma (PRP) and platelet poor plasma (PPP) and 3 ml blood without anticoagulant to obtain serum for lipid profile, cardiac enzyme and blood glucose assay.

CBC is performed with an automated analyzer Celldyne 3700, to obtain the haematoloical profile. The lipid profile, CK-MB and blood glucose level are assayed enzymatically by an automated analyzer Hitachi 902, to obtain the risk factors of the acute coronary syndrome. Troponin T is performed with sandwich method using Roche Cardiac analyzer.

Citrate tube is centrifuged at 100 g for 6 minutes to obtain Platelet Rich Plasma (PRP). The plasma is then centrifuged again at 1600–2000 g for 10 minutes to obtain Platelet Poor Plasma (PPP). Platelet aggregation test is done by a turbidimetric method using Helena Agram aggregometer. For the agonist are used ADP 1.5 and 10 µM and epinephrine 5 and 10 µM. Platelet aggregation test is done immediately after the PRP and PPP are obtained. As the platelets aggregate, and the light transmittance increase, they were measured in 10 minutes until the maximal platelet aggregation exist.

Statistical Analysis

The characteristic of the two groups is described in Table 1. which compare platelet aggregation induced by ADP and epinephrine in the acute coronary syndrome patients and normal control group. The independent t test is used for the comparison between the two groups if the data is normally distributed. While the Mann-Whitney test is used for the comparison of variables with an abnormal distribution. The significantly used in the analysis if p < 0.05.

THE RESULT AND DISCUSSION

In this study, were obtained 16 acute coronary syndrome patients, but 6 (six) of them were excluded and 10 normal people included as the control group.

In this study, the mean total cholesterol level, LDL and at random glucose level differ significantly between the acute coronary syndrome patients and the control group.

Table 1. The characteristic of 2 (two) subject groups

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>ACS (N=10)</th>
<th>Control (N = 11)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>9 (90%)</td>
<td>9 (81.8%)</td>
<td>p &gt; 0.05</td>
</tr>
<tr>
<td>Female</td>
<td>1 (10%)</td>
<td>2 (18.2%)</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>53.6 ± 10.48</td>
<td>51 ± 7.49</td>
<td>p &gt; 0.05</td>
</tr>
<tr>
<td>Thrombosis (10^3/µl/mm³)</td>
<td>269.9 ± 63.23</td>
<td>285 ± 85.95</td>
<td>p &gt; 0.05</td>
</tr>
<tr>
<td>Total Cholesterol (mg/dL)</td>
<td>200 ± 45</td>
<td>155 ± 22.28</td>
<td>p &lt; 0.05*</td>
</tr>
<tr>
<td>Triglyceride (mg/dL)</td>
<td>150.3 ± 67.5</td>
<td>105.18 ± 30.97</td>
<td>p &gt; 0.05</td>
</tr>
<tr>
<td>HDL (mg/dL)</td>
<td>36 ± 8.7</td>
<td>37.3 ± 8.31</td>
<td>p &gt; 0.05</td>
</tr>
<tr>
<td>LDL (mg/dL)</td>
<td>134.6 ± 44.5</td>
<td>98.27 ± 17.03</td>
<td>p &lt; 0.05*</td>
</tr>
<tr>
<td>Adr glucose (mg/dl)</td>
<td>182.6 ± 96.79</td>
<td>87.09 ± 12.86</td>
<td>p &lt; 0.05*</td>
</tr>
</tbody>
</table>

Note: * significant

Table 2. The 2 (two) groups platelet aggregation induced by ADP

<table>
<thead>
<tr>
<th>Agonist (µM)</th>
<th>ACS patients (n = 10)</th>
<th>Control (n = 11)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADP 1</td>
<td>17.16 ± 13.72</td>
<td>4.3 ± 2.83</td>
<td>p &lt; 0.05*</td>
</tr>
<tr>
<td>ADP 5</td>
<td>50.34 ± 17.01</td>
<td>34.84 ± 17.79</td>
<td>p &lt; 0.05*</td>
</tr>
<tr>
<td>ADP 10</td>
<td>75.43 ± 22.34</td>
<td>72.64 ± 13.11</td>
<td>p &gt; 0.05</td>
</tr>
</tbody>
</table>

Note: * significant

In this study, the platelet aggregation induced by ADP 1 and 5 µM differs significantly between the acute coronary syndrome patients and the control group.

Table 3. The 2 (two) groups platelet aggregation induced by Epinephrine

<table>
<thead>
<tr>
<th>Agonist (µM)</th>
<th>ACS patients (n = 10)</th>
<th>Control (n = 11)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPI 5</td>
<td>81.55 ± 27.09</td>
<td>72.13 ± 15.42</td>
<td>p &gt; 0.05</td>
</tr>
<tr>
<td>EPI 10</td>
<td>87.16 ± 48.32</td>
<td>77.12 ± 10.85</td>
<td>p &gt; 0.05</td>
</tr>
</tbody>
</table>

In this study, between the acute coronary syndrome patients and the control group there is no significant difference observed in the platelet aggregation which induced by epinephrine 5 and 10 µM. There is also no significant difference in the platelet aggregation induced by either ADP or epinephrine in the acute coronary syndrome patients with and without...
dyslipidemia, hypertension as well as those suffer diabetes mellitus. But there is a significant difference in the platelet aggregation induced by ADP 10 µM in the acute coronary syndrome patients aged above 50 years old (Table 4).

Table 4. patients aged < 50 years and > 50 years platelet aggregation

<table>
<thead>
<tr>
<th>Agonist</th>
<th>&lt; 50 years (n = 3)</th>
<th>&gt; 50 years (n = 7)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADP 1</td>
<td>13.81 ± 16.94</td>
<td>8.34 ± 6.36</td>
<td>p &gt; 0.05</td>
</tr>
<tr>
<td>ADP 5</td>
<td>48.61 ± 21.99</td>
<td>38.29 ± 16.11</td>
<td>p &gt; 0.05</td>
</tr>
<tr>
<td>ADP 10</td>
<td>82.1 ± 17.91</td>
<td>65.12 ± 14.62</td>
<td>p &lt; 0.05*</td>
</tr>
<tr>
<td>EPI 5</td>
<td>86.56 ± 25.12</td>
<td>70.5 ± 17.68</td>
<td>p &gt; 0.05</td>
</tr>
<tr>
<td>EPI 10</td>
<td>96.11 ± 51.17</td>
<td>73.15 ± 12.18</td>
<td>p &gt; 0.05</td>
</tr>
</tbody>
</table>

Note: * significant

In this study, is observed an increase in platelet aggregation with ADP and epinephrine in the acute coronary syndrome group, but this test is performed only once. No significant difference is found between dyslpidemia, hypertension, diabetes mellitus patients and the increase in the platelet aggregation case. There is a significant difference in the platelet aggregation induced by ADP 10 µM in patients aged above 50 years old. This is similar with the study carried out by Mardiana, which found significant increase in the platelet aggregation induced by ADP 5 and 10 µM in UAP patients.11 Yoshida found that in UAP patients, the platelet aggregation induced by ADP and the collagen in resting condition is lower than the control group, but it is increased after they exercise.12

Guha et al performed platelet aggregation test on patients which suffer acute coronary syndrome within 48 hours and 7 days after treatment with aspirin and clopidogrel. The platelet aggregation induced by epinephrine, ADP and collagen were higher at 48 hours after treatment, and higher in diabetic and smoker group.13

Hutajulu found that platelet aggregation was higher at the first day and decreased after 7 days, although still higher than the control group. The location of infarct and smoking habit didn’t affect the increase in platelet aggregation.14

Lakhay found significant increase in the platelet aggregation induced by all agonists (ADP epinephrine, collagen and thrombin) in myocardial infarct and angina patients. Aspirin consumption is associated with the decrease of platelet response. The highest incidence of myocardial infarct are found among 45–54 years old.15

**CONCLUSION**

From this study, in the acute coronary syndrome patients compared to the control group the researchers found a significant increase in the platelet aggregation response induced by ADP 1 and 5 µM. There was also found a significant increase in the platelet aggregation response induced by ADP 10 µM in patients aged above 50 years old.

**REFERENCES**


